



Suggested Formula	Chloroquine Phosphate 80.5 mg/5 mL Oral Liquid (Suspension, 10 mL)	FIN	F 001 479v2
-------------------	--	-----	-------------

Note: Chloroquine Phosphate 80.5 mg/5 mL is equivalent to Chloroquine 50 mg/5 mL

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Chloroquine Phosphate, USP	0.161	g				
Tutti Frutti Flavor	0.1	mL				
Medisca Oral Suspend (Suspending Vehicle)	4.9	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 10.0	mL				
Citric Acid 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible): Chloroquine Phosphate

Light Sensitive (protect from light whenever possible): Chloroquine Phosphate

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing errors and pH testing considerations during preparation, it is suggested to measure an additional **20 to 25%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Chloroquine Phosphate 80.5 mg/5 mL Oral Liquid (Suspension, 10 mL)	FIN	F 001 479v2
-------------------	--	-----	-------------

SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Chloroquine Phosphate, USP §	0.161	g			
Tutti Frutti Flavor	0.1	mL			
Medisca Oral Suspend (Suspending Vehicle)	4.9	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 10.0	mL			
Citric Acid 10% Solution	As required				

§ Weigh / measure just prior to use.

* Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction	
1.	<u>Powder preparation:</u> A. Triturate the Chloroquine Phosphate to form a fine, homogeneous powder.
2.	<u>Medium integration:</u> A. In the given order, sequentially add the following ingredients to the Oral Suspend (Suspending Vehicle): -Fine, homogeneous powder (Step 1A) -Tutti Frutti Flavor <u>Specifications:</u> Continuously mix. <u>End result:</u> Homogeneous liquid-like dispersion.
3.	<u>Filling to volume:</u> A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 2A) to fill to the required batch size (10.0 mL <i>plus</i> processing error adjustments). <u>Specifications:</u> Continuously mix. <u>End result:</u> Homogeneous liquid-like dispersion.



Suggested Formula	Chloroquine Phosphate 80.5 mg/5 mL Oral Liquid (Suspension, 10 mL)	FIN	F 001 479v2
-------------------	--	-----	-------------

4.	<p><u>pH testing:</u></p> <p>A. Draw an appropriate amount of the mixture (Step 3A).</p> <p>B. Test the pH of the sample. It should lie between 3.4 and 3.5.</p> <p>C. <u>If the pH > 3.5, carefully add the Citric Acid 10% Solution to the mixture:</u></p> <ol style="list-style-type: none">1. Draw and transfer 1 or 2 drops of the Citric Acid 10% Solution to the mixture.2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid.3. Re-test the pH.4. Continue to add the Citric Acid 10% Solution until a pH of 3.4 to 3.5 is obtained. <p>IMPORTANT: Do not allow the pH to fall below 3.4</p>
5.	<p><u>Product transfer:</u></p> <p>A. Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p> <p><u>Note:</u> Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.</p>



Suggested Formula	Chloroquine Phosphate 80.5 mg/5 mL Oral Liquid (Suspension, 10 mL)	FIN	F 001 479v2
-------------------	--	-----	-------------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date		Packaging Requirements	
	14 days, refrigerated, as per USP.		- Tightly closed, light-resistant dispensing bottle. - To be administered with a metered dose-measuring device.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6 Cap tightly after use.
	2	Keep out of reach of children.	7 Shake well before use.
	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	8 Keep refrigerated. Do not freeze.
	4	May impair mental and/or physical ability. Use care when operating a car or machinery.	9 Protect from light.
	5	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.	
Pharmacist Instructions	Add any auxiliary labels specific to the active to the dispensing container as deemed necessary.		
Patient Instructions	Contact your pharmacist in the event of adverse reactions.		



Suggested Formula	Chloroquine Phosphate 80.5 mg/5 mL Oral Liquid (Suspension, 10 mL)	FIN	F 001 479v2
-------------------	--	-----	-------------

REFERENCES

1.	Solutions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 157.
2.	Aralen. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2005</i> . 170.
3.	Chloroquine Phosphate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . London, England: The Pharmaceutical Press; 2005: 448.
4.	Chloroquine Phosphate (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 373.
5.	Chloroquine Phosphate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3rd Edition</i> . American Pharmaceutical Association; 2005: 93.
6.	Chloroquine Phosphate (Monograph). US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 394.
7.	USP <795>. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 2053.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.